Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

NCT02293005 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02293005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02293005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
May 20, 2015
Completion date
July 6, 2021
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, mesothelioma